(Q51356778)

4 April 2018

title

The value of visfatin in the prediction of metabolic syndrome: a multi-factorial analysis. (English)

1 reference

4 April 2018

1 reference

Alireza Esteghamati

1

1 reference

4 April 2018

Afsaneh Morteza

2

1 reference

4 April 2018

Ali Zandieh

3

1 reference

4 April 2018

Samira Jafari

4

1 reference

4 April 2018

Mehdi Rezaee

5

1 reference

4 April 2018

Manouchehr Nakhjavani

6

1 reference

4 April 2018

Arsia Jamali

7

1 reference

4 April 2018

Abdoul-Reza Esteghamati

8

1 reference

4 April 2018

Omid Khalilzadeh

9

1 reference

4 April 2018

language of work or name

English

0 references

publication date

15 May 2012

1 reference

4 April 2018

Journal of Cardiovascular Translational Research

published in

1 reference

4 April 2018

volume

5

1 reference

4 April 2018

issue

4

1 reference

4 April 2018

page(s)

541-546

1 reference

4 April 2018

https://scigraph.springernature.com/pub.10.1007/s12265-012-9373-8

exact match

0 references

cites work

The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

Type 2 diabetes mellitus: a disease of the innate immune system? An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

Visfatin: the missing link between intra-abdominal obesity and diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

Plasma visfatin concentrations and fat depot-specific mRNA expression in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

RETRACTED: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

Retraction: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

Overexpression of visfatin/PBEF/Nampt alters whole-body insulin sensitivity and lipid profile in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

Nampt: linking NAD biology, metabolism and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

Adipocytokines and the metabolic complications of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

The metabolic syndrome--a new worldwide definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

Adolphe Quetelet (1796-1874)--the average man and indices of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

The metabolic syndrome: a global public health problem and a new definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9373-8

An evaluation of visfatin levels in obese subjects.

21 January 2018

1 reference

12 December 2020

Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity.

1 reference

12 December 2020

Evaluation of new adipocytokines and insulin resistance in adolescents with polycystic ovary syndrome.

1 reference

12 December 2020

The adipokine visfatin is markedly elevated in obese children

1 reference

12 December 2020

Serum visfatin increases with progressive beta-cell deterioration

1 reference

12 December 2020

Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome

1 reference

12 December 2020

Appropriate waist circumference cut-off points among Iranian adults: the first report of the Iranian National Committee of Obesity.

1 reference

12 December 2020

10.1007/S12265-012-9373-8

Identifiers

DOI

1 reference

4 April 2018

1 reference

4 April 2018